Last reviewed · How we verify

NCT05025540

Automatic Segmentation Ultrasound-based Radiomics Technology in Diabetic Kidney Disease

Completed Last updated 16 February 2022
What this trial tests

trial testing ultrasonic imaging in Diabetic Kidney Disease in 499 participants. Completed in 1 December 2021.

Timeline
1 June 2021
Primary endpoint
1 December 2021
1 December 2021

Quick facts

Lead sponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment499
Start date1 June 2021
Primary completion1 December 2021
Estimated completion1 December 2021
Sites3 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 80, any sex, with Diabetic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diabetic kidney disease is a common complication of diabetes and the main cause of end-stage renal disease. In this study, the investigator plan to enroll nearly 500 participant with/without DKD and to develop an automatic segmentation ultrasound based radiomics technology to differentiating participant with a non-invasive and an available way.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Auto-Segmentation Ultrasound-Based Radiomics Technology to Stratify Patient With Diabetic Kidney Disease: A Multi-Center Retrospective Study.
    Chen J, Jin P, Song Y, Feng L, et al · · 2022 · cited 5× · PMID 35860551 · DOI 10.3389/fonc.2022.876967

Verify or expand the search:

Other recruiting trials for Diabetic Kidney Disease

Currently open trials in the same condition.

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05025540.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing